Kintor Pharmaceutical Limited kajeno e phatlalalitse hore k'hamphani e phethetse ho ngolisoa ha bakuli ba 160 bakeng sa teko ea eona ea bongaka ea mohato oa II ea KX-826 ("pyrilutamide") Chaena bakeng sa phekolo ea basali ba androgenetic alopecia (AGA) ka 4 March 2022, e nang le feela. e nkile likhoeli tse 'ne esale e qala.
Baahi ba ba nang le bothata ba ho lahleheloa ke moriri ba na le palo e kholo 'me ba atisa ho ba bacha,' me ho lahleheloa ke moriri butle-butle ho fetoha sepheo sa sechaba sohle. Qetellong ea 2020, palo ea ho lahleheloa ke moriri Chaena e ne e feta limilione tse 252. AGA, e tsejoang ka hore ke mofuta o atileng haholo oa ho lahleheloa ke moriri, ke boemo bo ka amang banna le basali. Chaena, ho ata ha AGA ke hoo e ka bang 21.3% ho banna le 6.0% ho basali.
Ngaka Youzhi Tong, mothehi, Molula-setulo, le CEO oa Kintor Pharma o ile a fana ka maikutlo a hore, "Re thabetse ho bona ho phethoa ha ho ngolisoa ha barupeluoa bohle tekong ea bongaka ea KX-826 ea mohato oa II, 'me ke rata ho leboha ka ho khethehileng. bafuputsi bohle, bafo le sehlopha sa ka ba nkileng karolo tekong ena ea bongaka. Chaena, mosali a le mong ho ba 20 ba baholo o na le bothata ba ho hlotheha ha moriri, ’me karo-karolelano ho banna ba baholo ke 5:1. Ho lahleheloa ke moriri ho na le phello ea bohlokoa ho bophelo bo botle ba kelello ba bakuli le boleng ba bophelo. Re labalabela ho fumana lintlha tsa pele ho tsoa thutong ena ea Q4 selemong sena, ho atolosa le ho feta bokhoni ba KX-826 ho bakuli ba AGA ba basali, le ho potlakisa teko ea KX-826 ea mohato oa III bakeng sa bakuli ba banna ba AGA naheng ea Chaena, e le ho kopana le litlhoko tsa kalafo tsa batho ba hlomohileng moriri kapele kamoo ho ka khonehang. ”
Teko ea mohato oa II ke thuto e sa reroang, e sa boneng habeli, e laoloang ke placebo, ea libaka tse ngata ho lekola katleho le polokeho ea KX-826 bakeng sa kalafo ea AGA ho basali ba baholo (N=160).
SEO U LOKELANG HO SE NKA HO SEHLOOHO ENA:
- Youzhi Tong, founder, Chairman, and CEO of Kintor Pharma commented, “We are delighted to see the completion of the enrollment of all subjects in the phase II clinical trial of KX-826, and I would like to give special thanks to all the investigators, subjects and my team who participated in this clinical trial.
- We look forward to receiving preliminary data from this study in Q4 this year, further broadening the clinical potential of KX-826 in female AGA patients, and accelerating KX-826’s phase III clinical trial for male AGA patients in China, so as to meet the treatment needs of people suffering from hair loss as soon as possible.
- The population of those who suffer from hair loss has a large number and tends to be younger, and hair loss is gradually becoming the focus of the whole society.
